Handelsavisen
prelaunch
Companies ›Healthcare ›PLSM.TA
PL
PLSM.TA — TASE (Tel Aviv) Healthcare Equipment

Plsm.Ta

$1 150,00
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-30,4 %
ROE
-19,1 %
Net margin
-39,6 %
Debt / equity
0,02
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

PLSM.TA develops and sells medical equipment, primarily focused on diagnostic and therapeutic devices for healthcare applications.

Business. PLSM.TA develops and sells medical equipment, primarily focused on diagnostic and therapeutic devices for healthcare applications.

Classification99 %
SectorHealth Care
Industry groupHealthcare Equipment
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
UBS Financial Services, Inc.
largest disclosed fund holder
Profitability→
-19,1 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning PLSM.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to PLSM.TA. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    PLSM.TA develops and sells medical equipment, primarily focused on diagnostic and therapeutic devices for healthcare applications.

    Classification99 %
    SectorHealth Care
    Industry groupHealthcare Equipment
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a low debt-to-equity ratio of 0.02, indicating a conservative leverage approach, and a strong current ratio of 7.88, suggesting robust short-term liquidity. With cash and equivalents amounting to 21.6 million ILS, the firm maintains a solid liquidity position, which is further supported by a low liquidity risk rating.

    Profitability metrics reveal a challenging financial performance, with a negative return on equity of -19.08% and a return on assets of -15.57%, both significantly below the industry median for Advanced Medical Equipment & Technology firms. The company reported a net loss of 15.85 million ILS, with operating losses of 12.16 million ILS, indicating operational inefficiencies or pricing pressures.

    Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data, but the absence of segment-specific revenue breakdowns suggests a lack of diversification or a single dominant product line. This could pose a risk if demand for its core offerings declines.

    Looking ahead, the company is expected to face continued financial pressure, as it reported a negative operating cash flow of 32.88 million ILS and a free cash flow of -13.06 million ILS. The outlook for the current fiscal year is negative, with no clear signs of improvement in the next fiscal year.

    Risk factors include the company's negative net income and operating income, which could lead to increased financial stress. However, the dilution risk is currently rated as low, and no immediate dilution events are expected based on the latest filings and disclosures.

    Recent events, including the latest financial filing, show a continuation of losses and negative cash flows, with no significant new product launches or strategic shifts disclosed in the available data.

    Key takeaways
    • PLSM.TA is operating at a loss, with a negative return on equity and assets, indicating poor profitability.
    • The company maintains a strong liquidity position with a high current ratio and significant cash reserves.
    • There is no immediate dilution risk, but the company's financial performance remains a concern.
    • The lack of segment and geographic diversification could increase exposure to market-specific risks.
    • The company's capital structure is conservative, with minimal debt and a strong equity base.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $1 150,00
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $83.1M
    Net cashⓘ
    $20.0M
    Current ratioⓘ
    7.9
    Debt / equityⓘ
    0.0
    ROAⓘ
    -15.6%
    ROEⓘ
    -19.1%
    Cash conversionⓘ
    207.0%
    CapEx / revenueⓘ
    -0.3%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-30,4 %Above median
    Net Margin-39,6 %Above median
    ROE-19,1 %Below median
    Capex / Rev-0,3 %Above P75
    D/E0,02Below median
    Cash Conv2,07Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • PLSM.TA Market data — financials · 2026-05-29

    Ownership & reference

    Top holders

    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    — missing data

    Short positioning

    322.5Kshares short+412.7% vs prior
    1days to cover
    33.0%short of daily vol
    467.5Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    PLSM.TACanonical
    TASE (Tel Aviv) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage